Piper Sandler Reiterates Overweight Rating on SI-BONE Inc. (SIBN)

Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $25.00 price target on SI-BONE Inc. (NASDAQ: SIBN).

The analyst commented, "Recently, we hosted meetings with management at SIBN. From a high level, the company continues to grow nicely on the topline while showing impressive leverage on the cash flow side of things. Recent product introductions have helped expand its surgeon call point, while every operating metric continues to improve including sales force productivity. We believe the overall end market, the SI Joint space, is underappreciated by investors as it offers durable growth in a capital light model which is a novelty in Ortho. Specifically, we believe SIBN is inappropriately being lumped in with other unprofitable small caps when upside to the Street’s current expectations for EBITDA look highly achievable."

For an analyst ratings summary and ratings history on SI-BONE Inc. click here. For more ratings news on SI-BONE Inc. click here.

Shares of SI-BONE Inc. closed at $13.60 yesterday.

You May Also Be Interested In

• JPMorgan Downgrades Tata Technologies (TATATECH:IN) to Underweight
• Barclays Starts Sigma Foods SAB DE CV (SIGMAFA:MM) at Overweight
• Kepler Cheuvreux Upgrades Azelis Group NV (AZE:BB) to Hold